Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Apieron
Patients with persistent, moderate to severe asthma will be randomized to receive therapy guided by either eNO and clinical standard of care (eNO group) or clinical standard of care (control group). An eNO treatment algorithm will be established for each patient in the eNO group at Baseline (Visit 1). Enrollment is estimated to be six months with a follow up period of twelve months.
Age
12–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Pre-existing diagnosis of asthma
Persistent, moderate or severe asthma as classified by NAEPP
Sub-optimally controlled asthma
Initiated ICS therapy for at least the past 30 days and a history of improvement of asthma control on steroids
You may not be if
Active cigarette smoking or ≥ 10 pack-years smoking history
Xolair taken in the past 6 months prior to enrollment
Oral prednisone taken in the last 4 weeks prior to enrollment
Cystic Fibrosis, COPD, ciliary dyskinesia, chest wall deformities or scoliosis
Subject is currently enrolled in another investigational drug study
